TY - JOUR
T1 - The societal burden of HBV-related disease
T2 - South Korea
AU - Yang, Bong Min
AU - Kim, Dong Joon
AU - Byun, Kwan Soo
AU - Kim, Hong Soo
AU - Park, Joong Won
AU - Shin, Sangjin
N1 - Funding Information:
Acknowledgments This study was supported in part by a research grant from the Novartis Pharmaceuticals Corporation.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/3
Y1 - 2010/3
N2 - To highlight the societal burden of HBV infection in South Korea, we estimated the annual societal costs of HBV-related diseases for the year 2005. For the economic costs of HBV-infection-related diseases estimate, baseline data was collected from the Health Insurance Review and Assessment Service (HIRA) database. To complement data from the HIRA database, hospital charts from sample hospitals was reviewed and patient surveys were conducted. In 2005, the societal cost of HBV infection was 1.937 trillion KRW, including 474,642 million KRW of direct costs and 1.463 trillion KRW of indirect costs. The cost breakdown by disease was CHB at 465,167 million KRW, cirrhosis at 533,449 million KRW, hepatocellular carcinoma at 863,940 million KRW, and liver transplantation at 74,635 million KRW. The estimated amount is equivalent to 0.24% of the 2005 Korean GDP. This analysis emphasizes how important the prevention and treatment of these diseases are from the perspectives of the Korean society.
AB - To highlight the societal burden of HBV infection in South Korea, we estimated the annual societal costs of HBV-related diseases for the year 2005. For the economic costs of HBV-infection-related diseases estimate, baseline data was collected from the Health Insurance Review and Assessment Service (HIRA) database. To complement data from the HIRA database, hospital charts from sample hospitals was reviewed and patient surveys were conducted. In 2005, the societal cost of HBV infection was 1.937 trillion KRW, including 474,642 million KRW of direct costs and 1.463 trillion KRW of indirect costs. The cost breakdown by disease was CHB at 465,167 million KRW, cirrhosis at 533,449 million KRW, hepatocellular carcinoma at 863,940 million KRW, and liver transplantation at 74,635 million KRW. The estimated amount is equivalent to 0.24% of the 2005 Korean GDP. This analysis emphasizes how important the prevention and treatment of these diseases are from the perspectives of the Korean society.
KW - Cost of illness
KW - Hepatitis B
KW - Prevalence
KW - South Korea
UR - http://www.scopus.com/inward/record.url?scp=77949331566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949331566&partnerID=8YFLogxK
U2 - 10.1007/s10620-009-0786-4
DO - 10.1007/s10620-009-0786-4
M3 - Article
C2 - 19333757
AN - SCOPUS:77949331566
VL - 55
SP - 784
EP - 793
JO - American Journal of Digestive Diseases
JF - American Journal of Digestive Diseases
SN - 0002-9211
IS - 3
ER -
